Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
121 studies found for:    "Sjogren syndrome" OR "Sjogren's Syndrome"
Show Display Options
Rank Status Study
21 Completed Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome
Condition: Sjögren's Syndrome
Intervention: Drug: LimphoStat-B
22 Completed A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome
Conditions: Dry Eye Syndromes;   Sjögren Syndrome
Intervention:
23 Recruiting Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome
Condition: Sjogren's Syndrome
Interventions: Drug: Belimumab;   Drug: Rituximab;   Drug: Placebo belimumab;   Drug: Placebo rituximab
24 Completed Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome
Condition: Primary Sjogren's Syndrome
Intervention: Drug: Mycophenolate sodium
25 Completed Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome
Condition: Primary Sjögren's Syndrome
Interventions: Drug: Hydroxychloroquine;   Drug: Placebo
26 Active, not recruiting PD of VAY736 in Patients With Primary Sjögren's Syndrome
Condition: Primary Sjögren's Syndrome
Interventions: Drug: VAY736;   Drug: Placebo
27 Withdrawn Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome
Condition: Primary Sjögren's Syndrome
Interventions: Drug: VAY736 lower dose;   Drug: VAY736 higher dose
28 Recruiting Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
Condition: Primary Sjögren's Syndrome
Interventions: Drug: CFZ533 active - Cohort 1;   Drug: CFZ533 placebo- Cohort 1;   Drug: CFZ533 active - Cohort 2;   Drug: CFZ533 placebo - Cohort 2
29 Completed A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome
Conditions: Dry Mouth Associated With Sjogren's Syndrome;   Xerostomia
Interventions: Drug: Placebo;   Drug: 552-02
30 Not yet recruiting Acupuncture for Primary Sjögren Syndrome
Condition: Sjogren's Syndrome
Interventions: Device: acupuncture group;   Device: Sham Acupuncture group
31 Enrolling by invitation Salivary Biomarkers for Sjögren's Syndrome Detection
Condition: Sjögren's Syndrome
Intervention:
32 Completed Rituximab Treatment in Sjogren's Syndrome
Condition: Sjogren's Syndrome
Intervention: Drug: rituximab (anti-CD20)
33 Completed Anti-CD20 Antibody Therapy for Sjogren's Syndrome
Condition: Sjogren's Syndrome
Intervention: Drug: Rituximab
34 Recruiting Early Detection of Pulmonary- and Pulmonary Vascular Disease in Sjögren Syndrome
Conditions: Sjögren Syndrome;   Pulmonary Hypertension
Intervention:
35 Completed Exploratory Study for Dry Mouth in Patients With Sjögren’s Syndrome
Conditions: Xerostomia;   Sjogren's Syndrome
Intervention: Drug: Rebamipide
36 Recruiting A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
Condition: Sjögren's Syndrome
Interventions: Drug: LY3090106;   Drug: Placebo
37 Recruiting A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
Condition: Sjogren's Syndrome
Interventions: Drug: Matching Placebo;   Drug: RO5459072
38 Not yet recruiting Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome
Condition: Sjogren's Syndrome
Interventions: Drug: Cyclosporin A;   Drug: Prednisone;   Drug: Placebo;   Drug: Calcium carbonate D
39 Not yet recruiting Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
Condition: Sjogren's Syndrome
Interventions: Drug: BMS-931699;   Drug: BMS-986142;   Drug: Placebo
40 Enrolling by invitation Confocal Microscopy and Lacrimal Gland in Sjogren's Syndrome
Condition: Primary Sjogren's Syndrome
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years